Ariela Katz

Articles

Urology Practice Keeps Up With Technology Through Physician-Owned Business Model

June 1st 2018

Greater Boston Urology strives to offer comprehensive urologic care that includes up-and-coming diagnostics and treatments, such as the Prostate Health Index blood test and high intensity–focused ultrasound.

Selinexor Tested in Combination With Standard Therapy in Multiple Myeloma

May 25th 2018

The BOSTON trial is randomizing patients with relapsed/refractory multiple myeloma to a triplet combination of selinexor (KPT-330), bortezomib (Velcade), and dexamethasone versus a combination of bortezomib and dexamethasone.

Study Findings Complicate the Paradigm for Hormone-Sensitive Prostate Cancer

May 21st 2018

Data from recent trials in metastatic hormone-sensitive prostate cancer have demonstrated the heterogeneous nature of prostate cancer and its subtypes, highlighting the importance of a more cautious approach in choosing therapies for patients.

Stemness Inhibitor Tested in Rare Hematologic Cancer

May 17th 2018

SL-401, a novel therapy that targets a cancer stemness pathway, is being investigated in patients with blastic plasmacytoid dendritic cell neoplasm in a phase I/II trial.

Urology Practice Uses Robotic Surgery to Improve Outcomes

May 5th 2018

Since 2005, physician partners at Comprehensive Urologic Care have been using a form of clampless surgery, which they developed at their practice, for partial nephrectomies.

Promising Umbralisib Combinations Tested in NHL Subtypes

May 3rd 2018

The phase IIb UNITY-NHL clinical trial is exploring the novel drug umbralisib as monotherapy or as part of a doublet or a triplet. The doublet includes ublituximab and the triplet includes ublituximab and bendamustine.

POUT Data Show Benefit of Adjuvant Chemotherapy in Patients With UTUC

April 11th 2018

Data from the phase III POUT clinical trial demonstrated that adjuvant platinum-based chemotherapy improves disease-free survival and metastasis-free survival in patients with upper tract urothelial carcinoma.

AKT Inhibitor May Overcome Chemotherapy Resistance in 2 Breast Cancer Subtypes

April 2nd 2018

A novel inhibitor that targets the AKT node in the PI3K pathway may offer a treatment option in cases of resistance to chemotherapy in 2 patient populations: triple-negative breast cancer or ER-positive/HER2-negative breast cancer with certain molecular aberrations.

Novel Radiolabeled ADC Could Improve Outcomes in High-Risk AML

April 2nd 2018

Older patients with active, relapsed, or refractory acute myeloid leukemia have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy.

Novel Lenvatinib Combinations Tested in Frontline RCC

March 22nd 2018

The current standard-of-care therapy for patients with clear cell renal cell carcinoma is sunitinib, but many patients relapse or don't have responses to the drug.

Novel Combo Explored for Rare Brain Tumor

March 5th 2018

Investigators are seeking to determine whether the combination of eflornithine with lomustine can improve survival for patients with recurrent anaplastic astrocytoma.

Flexible Scope Indication Approved for Bladder Imaging Agent

February 26th 2018

The FDA recently approved a supplemental new drug application for Blue Light Cystoscopy with Cysview for surveillance of bladder cancer. Cysview is currently indicated for use for detection of nonmuscle-invasive bladder cancer.

Urology Practice Succeeds With Transparency, Upfront Payment Model

February 25th 2018

Wichita Urology, the largest independent urology practice in Wichita, Kansas, have built their success over 60 years partly by holding frequent meetings, which they say build camaraderie and make it possible to address needs quickly.

Immunotherapy Combination Explored in Unresectable HCC

February 22nd 2018

Investigators are looking into a combination of immunotherapy agents for patients with unresectable hepatocellular carcinoma, for whom there are limited treatment options in the first line.

Clinical Testing of Pan-TRK Inhibitor Progresses Across Multiple Tumor Types

February 13th 2018

The pan-TRK inhibitor entrectinib (RXDX101) is being tested simultaneously in multiple locally advanced or metastatic solid tumor types as a treatment for patients harboring fusions involving the NTRK1/2/3, ROS1, or ALK genes.

Novel Antibody Tested in First-Line DLBCL Therapy

January 25th 2018

Investigators are studying the value of polatuzumab vedotin in patients with intermediate- or high-risk diffuse large B-cell lymphoma.

FGFR Inhibitor Tested in Hard-to-Treat GI Cancer

January 13th 2018

Given that few options are available for intrahepatic cholangiocarcinoma, investigators are excited about a phase III trial of the multikinase inhibitor derazantinib as a second-line treatment for patients with inoperable or advanced disease.

Three-Pronged Program Investigates Larotrectinib in Diverse Patient Population

January 5th 2018

Larotrectinib, an oral inhibitor of tropomyosin receptor kinases, is being developed in a novel multifaceted clinical trial program that spans cancer types and age groupings.

Plinabulin Combo With Docetaxel Aimed at Delivering a "Double Hit" in NSCLC Trial

January 3rd 2018

Plinabulin, an antineoplastic agent that activates an immune response, is being investigated as a treatment option for patients with advanced or metastatic non–small cell lung cancer who have progressed after standard-of-care therapy.

A Practice Model Designed to Reward Physician Partners Equally

December 14th 2017

Associated Medical Professionals of New York, a urology and radiation oncology practice, seeks to give its physician partners an equal share of its financial success while rewarding all staff members according to their levels of responsibility and workflow intensity.